ARTICLE | Targets & Mechanisms
D-coupling Multiple Myeloma's Codependents
May 8, 2008 7:00 AM UTC
Three years ago researchers at the Mayo Clinic Arizona reported that most types of multiple myeloma overexpress cyclin D1 and/or cyclin D2.1 Following on that earlier work, a new research team at the clinic has explored whether these proteins are viable targets for treating the disease-and if so, how to target them.
In the Journal of Clinical Investigation, the researchers reported that kinetin riboside, a naturally occurring cytokinin, inhibited multiple myeloma (MM) cell proliferation by suppressing the expression of cyclins D1 and D2 (CCND1; CCND2). The group suggests that derivatives of kinetin riboside could be more selective and less toxic to normal cells than current treatments for MM.2...